Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $1,032,750.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,215 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marion Mccourt also recently made the following trade(s):

• On Thursday, September 3rd, Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09.

Regeneron Pharmaceuticals Stock Down 1.0%

Shares of Regeneron Pharmaceuticals stock traded down $8.56 during trading hours on Thursday, hitting $843.47. 496,170 shares of the company’s stock traded hands, compared to its average volume of 839,664. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34. The company has a market cap of $86.84 billion, a PE ratio of 20.85, a PEG ratio of 1.61 and a beta of 0.19. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $729.93 and a 200-day simple moving average of $719.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported completion of a Phase 1/2 study evaluating its cemiplimab (Libtayo) combination with SNS-101. The update advances a potential oncology program, although no new efficacy results were disclosed. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: A market report projects continued growth in the global complement-inhibitors market through 2035 and lists Regeneron among the major industry participants, supporting the company’s longer-term opportunity but offering no company-specific financial update. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Analysts remain moderately optimistic about REGN’s outlook, with coverage highlighting its recent outperformance versus the broader healthcare sector. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Negative Sentiment: Multiple law firms are publicizing a securities class action focused on Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. The lawsuit alleges that the company’s disclosures about slowing event accrual and the trial protocol understated the risk of failing the primary endpoint; the trial ultimately failed, undermining earlier positive trial-risk messaging. Investors who purchased shares during the alleged class period may seek lead-plaintiff status by September 14, 2026. Hagens Berman Regeneron Securities Fraud Class Action Alert
• Negative Sentiment: The repeated litigation announcements increase headline, financial and reputational risk for Regeneron Pharmaceuticals (REGN). The core concern is that the failed melanoma study could delay or reduce expectations for a key growth opportunity and expose the company to potential damages and legal costs. REGN Investors Securities Fraud Lawsuit Notice

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. Finally, Birchwood Financial Partners Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $32,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on REGN. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald lifted their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.